Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.

Li C, Dong L, Su R, Bi Y, Qing Y, Deng X, Zhou Y, Hu C, Yu M, Huang H, Jiang X, Li X, He X, Zou D, Shen C, Han L, Sun M, Skibbe J, Ferchen K, Qin X, Weng H, Huang H, Song C, Chen J, Jin J.

Haematologica. 2020 Jan;105(1):148-160. doi: 10.3324/haematol.2018.208835. Epub 2019 Apr 11.

2.

Author Correction: Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe JR, Su R, Deng X, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C, Yang J, Chen J.

Nat Cell Biol. 2018 Sep;20(9):1098. doi: 10.1038/s41556-018-0102-7.

PMID:
29880862
3.

Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe JR, Su R, Deng X, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C, Yang J, Chen J.

Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23. Erratum in: Nat Cell Biol. 2018 Sep;20(9):1098.

4.

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2018 Feb 9;9(1):670. doi: 10.1038/s41467-018-02947-0.

5.

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification.

Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J.

Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.

6.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J.

Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.

7.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2017 Dec 13;8(1):2099. doi: 10.1038/s41467-017-02290-w. Erratum in: Nat Commun. 2018 Feb 9;9(1):670.

8.

ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.

Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, Qin X, Jin J, Chen J, Jiang X.

Sci Rep. 2017 May 12;7(1):1853. doi: 10.1038/s41598-017-01913-y.

9.

Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril.

Eichenbaum G, Skibbe J, Parkinson A, Johnson MD, Baumgardner D, Ogilvie B, Usuki E, Tonelli F, Holsapple J, Schmitt-Hoffmann A.

J Pharm Sci. 2012 Mar;101(3):1242-52. doi: 10.1002/jps.22816. Epub 2011 Nov 17.

PMID:
22095741
10.

[Rational diagnostics of acute abdomen].

Schildberg CW, Skibbe J, Croner R, Schellerer V, Hohenberger W, Horbach T.

Chirurg. 2010 Nov;81(11):1013-9. doi: 10.1007/s00104-010-1938-y. German.

PMID:
20464353
11.

An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.

Nassar AE, King I, Paris BL, Haupt L, Ndikum-Moffor F, Campbell R, Usuki E, Skibbe J, Brobst D, Ogilvie BW, Parkinson A.

Drug Metab Dispos. 2009 Sep;37(9):1922-30. doi: 10.1124/dmd.109.027516. Epub 2009 Jun 11.

PMID:
19520774

Supplemental Content

Loading ...
Support Center